tldrdaily.news logo

Eli Lilly's Zepbound Awaits FDA Approval for Sleep Apnea Treatment

1 min read
Source: CNBC
Eli Lilly's Zepbound Awaits FDA Approval for Sleep Apnea Treatment
Photo: CNBC
TL;DR Summary

Eli Lilly has applied for FDA approval of its weight loss drug Zepbound for treating obstructive sleep apnea (OSA) and expects a decision by the end of the year. If approved, the drug could launch in early 2025. Recent trials show Zepbound significantly reduces OSA severity, potentially offering an alternative to current treatments like PAP machines.

Topics:top-news#eli-lilly#fda#health#sleep-apnea#weight-loss-drug#zepbound
Share this article
  1. Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year  CNBC
  2. Weight-Loss Drug Zepbound Offers a New Way to Treat Sleep Apnea  The New York Times
  3. Study identifies first drug therapy for sleep apnea  Medical Xpress
  4. Eli Lilly seeks FDA’s OK to expand Zepbound’s uses to include sleep apnea  MarketWatch
  5. Weight-Loss Drug Zepbound Resolves Sleep Apnea in up to 52% of Patients, Lilly Says  U.S. News & World Report

Reading Insights

Total Reads

0

Unique Readers

3

Time Saved

4 min

vs 5 min read

Condensed

94%

901 → 56 words

Want the full story? Read the original article

Read on CNBC